The Medical Letter on Drugs and Therapeutics
Inhaled Loxapine (Adasuve) for Acute Agitation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an inhalation powder formulation of loxapine (Adasuve – Teva), a first-generation antipsychotic long available in an oral formulation, for treatment of acute agitation related to schizophrenia or bipolar I disorder in adults. Adasuve is the first inhaled drug to be approved for this indication.

STANDARD TREATMENT — Acute agitation in patients with schizophrenia or bipolar I disorder is usually managed with short-acting intramuscular antipsychotics, sometimes supplemented with a benzodiazepine.1 First-generation antipsychotics are more likely to cause tardive dyskinesia, neuroleptic malignant syndrome, and extrapyramidal symptoms than second-generation agents. All antipsychotic medications contain a boxed warning about an increased risk of death among elderly patients with dementia.

CLINICAL STUDIES — Approval ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Inhaled Loxapine (Adasuve) for Acute Agitation
Article code: 1440c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian